• Finance Tax Investment

BIA analysis of 2021 Budget

The Chancellor has said that business support measures such as Furlough will continue, and more money has been made available to vaccine programmes. But alongside these measures to mitigate the impact of the pandemic, there was a promise of more investment in science and tech scale-ups, improvements to R&D tax credits to incentivise cutting edge science to be conducted in the UK, and rule changes to make it easier to list on the London Stock Exchange.

Fieldfisher Life Sciences sector group advised on £370 million of ECM transactions in 2020

Fieldfisher’s Band 1 ranked equity capital markets team advised on approximately £370 million worth of deals within the life sciences and healthcare sector last year.

Fieldfisher advises Panmure Gordon on fundraising for Diurnal Group Plc of up to £10m

We're delighted to announce that Fieldfisher's leading equity capital markets team represented Panmure Gorden (UK) Limited on the oversubscribed fundraising for Diurnal Group Plc of up to £10m.

Fieldfisher advises Synairgen plc on fundraising of up to £87 million to support Phase III trials of its potential COVID-19 treatment

European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in Southampton, on its £87 million fundraising to begin the Phase III trial for a potential inhaled treatment for COVID-19

Synthetic Biology start up NanoSyrinx secures capital to develop its fully customisable platform for intra-cellular engineering

NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space.

Growth continues at Discovery Park as new tenants arrive

Psyros Diagnostics & VisusNano join innovation community

VisusNano opens new facility at Discovery Park and receives additional Innovate UK funding to accelerate revolutionary intraocular lens technology

Medtech company VisusNano announces the opening of its 800 sq. ft facility at Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing companies.

Advanced Therapy Treatment Centre network awarded £9.5m further investment

The UK Government grant will support new and existing projects until March 2022. Funding will ensure that the positive impact of the ATTC network continues; further optimising the UK ecosystem for routine adoption of advanced therapies.

AskBio Awarded £2m Scottish Enterprise R&D Grant to Help Reduce Barriers to Mainstream Gene Therapy

AskBio announces the award of a £1.99m R&D Grant from Scottish Enterprise. AskBio will invest £3.4m alongside the grant to fund research into the manufacturing challenges associated with scaling gene therapies for widespread patient access, to further develop technologies to improve the safety and efficacy of current therapies, and to enable the treatment of genetic diseases with more complicated disease pathways that the industry is not yet able to address.

Fieldfisher advises Excelya on the acquisition of three European Contract Research Organisations

A Fieldfisher cross-disciplinary and cross-border team, led by Philippe Netto, Hélène Lefebvre and Antoine Gabizon, advised Excelya, a leading European CRO (contract research organisation).